Search clinical trials for: indacaterol/glycopyrrolate

Total 289 results

Novartis

Completed

Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

France, Germany, Belgium, Spain, Turkey, Italy, Canada, Australia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Belgium, Netherlands, Canada, United States
University of Michigan
National Heart, Lung, and Blood Institute (NHLBI)

Completed

RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative (RETHINC)

COPD (Chronic Obstructive Pulmonary Disease)

United States
Novartis Pharmaceuticals

Completed

Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma (QAB149)

Asthma

United States
Yuan-Ming Luo

Completed

Comparison of Tai Chi and Pulmonary Rehabilitation on the Effect of Indacaterol in Treatment naïve COPD Participants

Chronic Obstructive Pulmonary Disease

China
Novartis Pharmaceuticals

Completed

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol (REVERBREZ)

Chronic Obstructive Pulmonary Disease (COPD)

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma

Asthma

South Africa, Belgium, Croatia, Turkey, Hungary, Colombia, Slovakia, Philippines, Russian Federation, Guatemala, Germany
University of Saskatchewan

Completed

Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve

Asthma

Canada
University Medical Center Groningen
Novartis

Completed

Anti-inflammatory Effects Glycopyrronium

Asthma | Allergic Asthma

Netherlands
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

China, Australia, India
Morten Hostrup, PhD

Recruiting

U-LABA/ICS Effects on Exercise Performance, Indacaterol

Exercise Performance

Denmark
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (GLOW6)

Chronic Obstructive Pulmonary Disease (COPD)

Greece, Belgium, Bulgaria, Turkey, Hungary, Slovakia, Spain, United Kingdom, Russian Federation, Ireland
Novartis Pharmaceuticals

Completed

A Study to Evaluate the Effects of Indacaterol Maleate as a New Formulation in the Concept 1 Device

Asthma

Germany, United Kingdom
Taipei Medical University Shuang Ho Hospital

Unknown

Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program

Chronic Obstructive Pulmonary Disease

Taiwan
Novartis Pharmaceuticals

Completed

Indacaterol EfectIveness In COPD Patients With Tuberculosis History (INFINITY)

Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis

Korea, Republic of
Novartis

Completed

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Chronic Obstructive Pulmonary Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Pharmacokinetics of Different Regimens of Indacaterol

Persistent Asthma

United States, Netherlands, United Kingdom, France, Germany, Jordan
Orion Corporation, Orion Pharma

Completed

Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler (FINDA)

Healthy Volunteers

Finland
Novartis Pharmaceuticals

Completed

Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Chronic Obstructive Pulmonary Disease

United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Salts in Patients With Asthma

Asthma

Italy, Germany, France
Novartis

Completed

12-week Efficacy of Indacaterol

Chronic Obstructive Pulmonary Disease

United States
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, New Zealand, Belgium
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Orion Corporation, Orion Pharma

Completed

Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product (FORELLI)

Healthy Volunteers

Finland
Novartis

Completed

Dose Ranging Study of Indacaterol in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Japan
Journey Medical Corporation

Completed

A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

Hyperhidrosis

United States
Novartis Pharmaceuticals

Completed

Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Taiwan, Korea, Republic of, Japan, India, Hong Kong, Singapore
Novartis Pharmaceuticals

Completed

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (SHINE)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Russian Federation, Taiwan, Canada, Germany, Philippines, South Africa, Spain, United Kingdom, Turkey, Hungary, Guatemala, Australia, Bulgaria, France, Poland, Switzerland, Slovakia, Japan
Sunovion Respiratory Development Inc.

Completed

Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease
Novartis Pharmaceuticals

Completed

A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Sweden, Denmark, Norway
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Novartis

Completed

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Hepatic Insufficiency

United States
Novartis

Completed

An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)

Chronic Obstructive Pulmonary Disease

Germany
Novartis Pharmaceuticals

Completed

Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study) (POWER)

Chronic Obstructive Pulmonary Disease

Canada
Novartis Pharmaceuticals

Completed

Efficacy, Safety, Tolerability, and Pharmacokinetics of Indacaterol Maleate Via Concept1 or Simoon Devices

Asthma

Germany, Netherlands, United Kingdom
Novartis Pharmaceuticals

Completed

Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations

Chronic Obstructive Pulmonary Disease

Hong Kong
Novartis

Completed

Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects

Healthy

India
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

COPD

Germany, Belgium, Poland, Romania, Italy, Spain, Estonia, Russian Federation, Austria, France, Slovakia, Czechia, Latvia, Lithuania, Greece, Hungary, United Kingdom, Portugal, Ireland, Norway, Slovenia, Denmark, Sweden
Novartis

Completed

Effect of Indacaterol on Inspiratory Capacity and Lung Function in Patients With COPD Versus Placebo and Formoterol

COPD

United Kingdom
Novartis Pharmaceuticals

Completed

Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

Asthma

United States
Novartis Pharmaceuticals

Completed

Cardiac Safety of Indacaterol

Chronic Obstructive Pulmonary Disease | Healthy Volunteers

United States
Novartis Pharmaceuticals

Completed

Indacaterol 75 μg Compared to Placebo, Assessing Time to Patient's Perception of Onset of Effect in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

COPD

United States
Novartis

Completed

Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)

COPD

United States, Argentina, Germany, Spain, Canada, India, Turkey, Sweden, Italy
Novartis Pharmaceuticals

Completed

Efficacy and Safety Study of QVA149 in COPD Patients

Chronic Obstructive Pulmonary Disease

United States
Centro Cardiologico Monzino
Novartis

Completed

Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation

Heart Failure

Italy
Novartis Pharmaceuticals

Completed

12-week Open-label Evaluation of Efficacy and Safety of Indacaterol (MOVE-ON)

Chronic Obstructive Pulmonary Disease (COPD)

Israel
Centre Hospitalier Universitaire de Besancon

Completed

Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD) (LAB-Card)

Chronic Obstructive Pulmonary Disease

France
Novartis Pharmaceuticals

Completed

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

COPD

Korea, Republic of
Novartis

Completed

The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Spain, Belgium, Italy, Canada, Denmark, United States
Eunah Cho, MD

Completed

Benefits of Glycopyrrolate on Intubation With Rigid-videostylet (OptiScope®)

Cholecystitis, Acute

Korea, Republic of

3

Subscribe